SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Consumer Healthcare gains on getting CCI’s nod for merger deal with HUL

28 Jan 2019 Evaluate

Glaxosmithkline Consumer Healthcare is currently trading at Rs. 7300.00, up by 14.90 points or 0.20% from its previous closing of Rs. 7285.10 on the BSE.

The scrip opened at Rs. 7315.00 and has touched a high and low of Rs. 7319.55 and Rs. 7251.00 respectively. So far 123 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 7934.85 on 18-Dec-2018 and a 52 week low of Rs. 5725.00 on 02-Apr-2018.

Last one week high and low of the scrip stood at Rs. 7329.00 and Rs. 7172.00 respectively. The current market cap of the company is Rs. 30629.05 crore.

The promoters holding in the company stood at 72.46%, while Institutions and Non-Institutions held 12.01% and 15.54% respectively.

GlaxoSmithKline Consumer Healthcare has received an approval from the Competition Commission of India (CCI) for its merger deal with Hindustan Unilever (HUL).

The scheme remains subject to the receipt of other necessary statutory and regulatory approvals under applicable laws, including by the NSE, SSE, SEBI, NCLT and the respective shareholders and creditors of HUL and the company.

Glaxosmithkline Consumer Healthcare’s core business is manufacturing of health drinks under the brand Horlicks.

Glaxo.Cons. Health Share Price

9696.40 0.00 (0.00%)
15-Apr-2020 18:01 View Price Chart
Peers
Company Name CMP
Varun Beverages 474.05
Nestle 1285.65
Britannia Inds 5733.75
LT Foods 422.10
Hatsun Agro Product 979.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×